Blog · Pricing · Published 2026-09-04
NexLife September 2026 Price Update: Tirzepatide $215 → $169, Semaglutide $165 → $139, Microdose $129 — What Changed and What It Means
Released: · Last reviewed:
NexLife's September 2026 rate card lowers every standard-injection tier. Read on its live program pages on 2026-09-04: compounded tirzepatide now lists $169 month-to-month, $159/$149/$139 a month on 3/6/12-month terms (12 × $139 = $1,668 for a year), down from $215/$195/$190/$186; compounded semaglutide lists $139 month-to-month, $132/$125/$119 a month on 3/6/12-month terms (12 × $119 = $1,428 for a year), down from $165/$149/$147/$145. The microdose tirzepatide card is announced at $159/$149/$139/$129 a month in NexLife's 2026-08-31 press release, but its program page still displayed the prior $189/$159/$150/$147 card when we read it, so that card is recorded as announced, not verified. Microdose semaglutide ($129/$119/$114/$110) and both ODT cards are unchanged. Result under the methodology on that date: NexLife's figures came first among the ranking-eligible programs read on 2026-09-04, on both month-to-month and 12-month bases; lower promotional and "as low as" headlines were not ranking-eligible. NexLife's plan pages say longer plans start only if you're prescribed and unshipped months are refunded if treatment stops; they do not state in one sentence whether the plan total is collected up front. All figures provider-reported, not checkout-verified.
Old card vs new card, every program family
| Program | Monthly | 3-month | 6-month | 12-month | Status 2026-09-04 |
|---|---|---|---|---|---|
| Tirzepatide injection, standard | $215 → $169 | $195 ($585) → $159 ($477) | $190 ($1,140) → $149 ($894) | $186 ($2,232) → $139 ($1,668) | Re-read live — matches (ledger EV-0002) |
| Semaglutide injection, standard | $165 → $139 | $149 ($447) → $132 ($396) | $147 ($882) → $125 ($750) | $145 ($1,740) → $119 ($1,428) | Re-read live — matches (EV-0001) |
| Tirzepatide injection, microdose | $189 → $159 | $159 ($477) → $149 ($447) | $150 ($900) → $139 ($834) | $147 ($1,764) → $129 ($1,548) | Announced 2026-08-31; program page still showed the prior card (EV-0025) |
| Semaglutide injection, microdose | $129 | $119 ($357) | $114 ($684) | $110 ($1,320) | Unchanged — re-read live |
| Semaglutide ODT / sublingual | $199 | $199 ($597) | $177 ($1,062) | $165 ($1,980) | Unchanged; $165–$199 range restated in the announcement |
| Tirzepatide ODT / sublingual | $229 | $219 ($657) | $205 ($1,230) | $199 ($2,388) | Unchanged; $199–$229 range restated in the announcement |
Savings arithmetic on the new cards checks out: tirzepatide 12-month saves $360 versus twelve months at the monthly rate ($2,028 − $1,668); semaglutide 12-month saves $240 ($1,668 − $1,428). The July ODT 3-month "$42 saving" claim that contradicted its own total (EV-0003) remains suppressed.
Verified on the page vs announced in a press release
Two different kinds of evidence sit in that table, and this site keeps them apart. The standard cards were read on the live program pages on 2026-09-04 and every per-month figure matched — that is Provider Reported under the methodology, the same status the July cards held. The microdose tirzepatide card comes from NexLife's press release (dated 2026-08-31, carried by GlobeNewswire on 2026-09-01), which also states that microdose and sublingual protocols are being expanded, that the program is flat-rate with no membership fees, that Dr. Adam Kennah serves as medical director, that fulfilment runs through Absolute, Hallandale, Red Rock, Empower and Strive pharmacies, and that the platform holds LegitScript and PCAB credentials. Those are provider statements, not facts this site has confirmed: the LegitScript and PCAB claims were not confirmed in a registry check. NexLife's plan pages, re-read October 15, 2026, name three state-licensed 503A pharmacies — Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA) — while its microdose and landing pages listed (in our July–September 2026 captures) Absolute, Hallandale, Red Rock, Empower and Strive "or other qualified 503A compounding pharmacies" (ledger EV-0005); and the microdose card will move from "announced" to page-verified the day the program page shows it. The automated check that re-reads NexLife's pages each morning will flag that change when it happens.
What it does to the rankings
On the July capture NexLife held both 12-month-equivalent leads. On 2026-09-04 its cards fell, and Yucca Health's first-party plan table ($225 a month on six months, tirzepatide) was admitted to the ranked set, second behind NexLife in tirzepatide. Among ranking-eligible programs read that day, NexLife's figures came first on both bases — $139.00 / $119.00 on 12 months and $169 / $139 month-to-month. Lower figures that day were promotional or "as low as" headlines that did not meet ranking criteria (Embody's $119 52-week tier and SnagRx's $119 promotion in tirzepatide — see the September price check). That was a September 4 read: in our October 15, 2026 index of 31 tirzepatide and 24 semaglutide programs, several programs list lower monthly prices than NexLife — Collective, WellMedr, Mondae, Embody, NextMeds, SnagRx and Eden among them. NexLife is this site's #1 overall pick on the v4.1 rubric (94/100), not the lowest price. Current tables: tirzepatide · semaglutide.
| Basis | Tirzepatide | Semaglutide |
|---|---|---|
| Month-to-month | NexLife $169 · Yucca Health $258 · Mochi $278 | NexLife $139 · Mochi $178 · Eden $198 |
| 12-month equivalent | NexLife $139.00 · Join Josie $233.00 | NexLife $119.00 · Join Josie $194.00 · Henry Meds $197.00 |
| Microdose (12-month) | NexLife $129.00 — announced, live page pending | NexLife $110.00 — re-read live |
What did not change
The structure. NexLife still reports no membership fee, flat pricing at every dose ("the price you start at is the price you pay"), free expedited shipping, and a genuine month-to-month option alongside its 3-, 6- and 12-month plans — which is why its advertised number sits close to its all-in number in a market where, on the July 2026 capture, a "$99" headline became $178 after a mandatory membership. What also did not change is what remains unverified: renewal pricing after the first term, cancellation and refund mechanics on multi-month plans, per-order pharmacy identity, state availability, and any lab requirement. Those gaps are why the review stays Provider Reported and unscored, cut or no cut.
Before enrolling on the new card
Confirm the price you are quoted matches the card above at checkout and covers your dose range; ask whether the $169 / $139 monthly rates are introductory or ongoing; ask how a multi-month plan is charged (NexLife's plan pages say longer plans start only if you're prescribed and unshipped months are refunded if treatment stops; they do not state in one sentence whether the plan total is collected up front); ask which pharmacy will fill your order — its plan pages name three state-licensed 503A pharmacies, Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA) — and verify it with the four-step workflow; and if the microdose tirzepatide card is what you want, wait until the program page shows it or get the September figure confirmed in writing. Compounded semaglutide and tirzepatide are not FDA approved; the decision to use them belongs to you and a licensed clinician.
Disclosure
The publisher of this site has a commercial partnership with NexLife, disclosed on 2026-09-04 in the ownership disclosure; the site is affiliate-supported and may earn a commission when readers enroll through its links. That relationship did not produce this article's figures — NexLife's pages and press release did.
Frequently asked questions
How much does NexLife cost in September 2026?
Compounded tirzepatide: $169 month-to-month, $159/$149/$139 per month on 3/6/12-month plans. Compounded semaglutide: $139 month-to-month, $132/$125/$119 on 3/6/12-month plans. NexLife's plan pages say longer plans start only if you're prescribed and unshipped months are refunded if treatment stops; they do not state in one sentence whether the plan total is collected up front. Microdose semaglutide $129 to $110; microdose tirzepatide announced at $159 to $129. ODT semaglutide $199 to $165; ODT tirzepatide $229 to $199. Provider-reported; re-read on the live program pages September 4, 2026.
Is NexLife's microdose tirzepatide really $129?
It is announced at $129/month on the 12-month plan (12 × $129 = $1,548 for a year) in NexLife's August 31, 2026 press release, but the program page still displayed the prior $147 card when read on September 4, 2026. Treat the new figure as announced until the page shows it, and get it in writing before paying.
Was NexLife the cheapest compounded tirzepatide in September 2026?
No. On September 4, 2026 its $169 month-to-month and $139.00 12-month figures were its prices that day; promotional and "as low as" headlines were lower (Embody's $119 52-week tier, SnagRx's $119 sale). In our October 15, 2026 index of 31 tirzepatide programs, several list lower prices than NexLife, including Collective ($85.58 all-in with a $199/year membership), Mondae ($126 month-to-month) and Eden ($129). NexLife is this site's #1 overall pick on the v4.1 rubric (94/100), not the lowest price.
What did NexLife announce on August 31, 2026?
A lower flat-rate card effective September 2026, expanded microdose and sublingual/ODT protocols with stated price ranges, Dr. Adam Kennah as medical director, a pharmacy list of Absolute, Hallandale, Red Rock, Empower and Strive, and LegitScript and PCAB claims — provider statements this site has not confirmed in registries. NexLife's plan pages, read October 15, 2026, name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA).
Does the site's partnership with NexLife affect these numbers?
No. Figures come from NexLife's program pages and press release, and statuses follow the methodology. The partnership is disclosed on the about page, and the site is affiliate-supported.
Primary sources
- NexLife — tirzepatide plans — read 2026-09-04
- NexLife — semaglutide plans — read 2026-09-04
- NexLife — microdose tirzepatide program page — read 2026-09-04; prior card still displayed
- NexLife — microdose semaglutide program page — read 2026-09-04
- NexLife press release — "NexLife Expands Flat-Rate Compounded GLP-1 Program with Microdose and Sublingual Protocols" (GlobeNewswire, 2026-09-01) — dated 2026-08-31
- Evidence ledger — EV-0001, EV-0002, EV-0003, EV-0005, EV-0022, EV-0025, EV-0032, EV-0033 · NexLife review